Benjamin Levy, MD

Articles

Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study

June 29th 2023

Overview and clinical implications of the CheckMate-816 study of neoadjuvant nivolumab plus platinum chemotherapy versus chemotherapy alone in early-stage NSCLC.

Selecting Optimal Treatment in Early-Stage NSCLC

June 23rd 2023

Ben Levy, MD offers insight into how he approaches the selection of the optimal treatment strategy in early-stage non-small cell lung cancer.

Overview of Early-Stage NSCLC and Molecular Testing

June 23rd 2023

A panel of experts who treat patients with non-small cell lung cancer provides an overview of staging, molecular testing and treatment options in stage I-IIIB non-small cell lung cancer.

The Future of Molecular Testing in NSCLC

November 9th 2022

The panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.

Financial Considerations with Molecular Testing for Patients With NSCLC

November 9th 2022

Drs Morganstein and Ramkumar detail the financial considerations patients and physicians face during the process of molecular testing for NSCLC.

Receiving Molecular Testing Results for NSCLC

November 2nd 2022

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share if they believe there should be a standard for molecular testing reports, and how frequently they communicate with their patients during the process.

Integrating Molecular Testing Results into Electronic Medical Records

November 2nd 2022

The panel reflects on challenges with the EMR, and the impact it has on treatment decision making for their patients with NSCLC.

Using Liquid Biopsy for Molecular Testing in NSCLC

October 26th 2022

Bhuvana Ramkumar, MD, highlights the strengths of liquid biopsy for molecular testing in NSCLC.

Types of Tissue Next-Generation Sequencing Platforms in NSCLC

October 26th 2022

Experts discuss the types of genotype panels they often use for testing patients with NSCLC, and why.

Average Turnaround Time for NSCLC Molecular Testing

October 19th 2022

Dr Neil Morganstein explains the typical turnaround times for molecular testing he sees and the challenges that prolong the process.

Best Practices for Accurate Tissue Genotyping in NSCLC

October 19th 2022

Dr Bhuvana Ramkumar shares best practices for molecular testing in NSCLC to obtain the most accurate results.

Enhancing Communication Among the Multidisciplinary Care Team

October 12th 2022

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share standards of communication among the care team at their clinical practice sites.

Challenges With and Strategies for Tissue Procurement in NSCLC

October 12th 2022

Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC.

Dr. Levy on the Approval of Trastuzumab Deruxtecan in HER2-Mutant NSCLC

August 19th 2022

Benjamin Levy, MD, discusses the significance of the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Dr. Levy on the Efficacy of Datopotamab Deruxtecan Plus Pembrolizumab in NSCLC

August 9th 2022

Benjamin Levy, MD, discusses the efficacy findings of the combination of datopotamab deruxtecan and pembrolizumab, with or without chemotherapy, in non–small cell lung cancer.

Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer

July 13th 2022

Dr Levy presents updated safety and efficacy results on larotrectinib in patients with TRK fusion-positive lung cancer.

Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer

July 13th 2022

Dr Benjamin Levy reviews long-term, pooled safety and efficacy data on larotrectinib in patients with TRK fusion-positive cancers.

Closing Expert Perspectives on Treatment in Advanced NSCLC

June 2nd 2022

Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.

Emerging Antibody Drug Conjugates in the Lung Cancer Treatment Landscape

June 2nd 2022

Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.

Recent Advances in Treatment of ROS1-Rearranged NSCLC

May 25th 2022

Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.